Author Archives: admin

‘Keep a Close Eye On’ This Regenerative Medicine Firm – Streetwise Reports (registration)

By adminAugust 17, 2017Uncategorized

In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."

Zhou summed up Cellular Biomedicine Group Inc.'s (CBMG:NASDAQ) recent activities in an Aug. 9 research report. "CBMG's cell therapy programs continue to make progress," she wrote. "We expect to see data from both the CARD-1 and CALL-1 chimeric antigen receptor T-cell (CAR-T) studies by 2017E, setting the stage for a value inflection as CBMG becomes a Phase 2 CAR-T player."

The analyst also noted the company has enough cash to get to that stage. "CBMG ended the period with $27M in cash," Zhou noted. "At the current burn rate, we estimate CBMG has sufficient capital to fund through topline data releases (by 2017E) from its CARD-1 and CALL-1 studies, which should represent catalysts for the stock."

She reiterated what the company's two China-based Phase 1 studies consist of:

1. Initiated in Q1/17, CALL-1 is a "dose-escalation study (n=9) that uses the optimized proprietary C-CAR011 construct of CD19 CAR-T therapy in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia. . .Good data should translate into a larger Phase 2 trial," Zhou wrote.

2. CARD-1 is a "nine-patient, dose escalation study evaluating safety efficacy and C-CAR011 cell persistence in patients with relapsed or refractory diffuse large B-cell lymphoma. . .Patient enrollment (n=9) is currently underway," said Zhou.

In other news, Cellular Biomedicine "received a $2.3M award from California Institute for Regenerative Medicine to support the company's allogeneic human adipose-derived mesenchymal stem cells AlloJoin for the treatment of knee osteoarthritis in the U.S.," indicated Zhou.

Looking forward, by the end of 2017, the biomedicine firm "expects to have a combined 70,000 square feet of GMP manufacturing space between Shanghai, an expanded Wuxi-based facility and the facility in Beijing," said Zhou. "These three facilities could simultaneously support clinical development of five CAR-T and stem cell therapy products, or up to 10,000 patient CAR-T treatments and 10,000 stem cell therapies per year."

These developments are the result of Cellular Biomedicine's previously announced collaboration with GE Healthcare Life Sciences China, Zhou added, "to co-develop industrial control processes in CAR-T and stem cell manufacturing."

Maxim Group has a Buy rating and 12-month target price of $18 per share on the company. Its stock currently trades at roughly $8.50 per share.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure: 1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: none. She or members of her household are paid by the following companies mentioned in this article: None. 2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. 4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

Disclosures from Maxim Group, Cellular Biomedicine Group, Company Update, Aug. 9, 2017

I, Gabrielle Zhou, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

I, Jason Kolbert, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

I, Jason McCarthy, Ph.D., attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firms total revenues, a portion of which is generated by investment banking activities.

Maxim Group provides non-investment banking securities-related services to Cellular Biomedicine Group for the execution of its employee stock purchase plan.

Maxim Group makes a market in Cellular Biomedicine Group.

Maxim Group expects to receive or intends to seek compensation for investment banking services from Cellular Biomedicine Group in the next 3 months.

Hypothermia after stroke reduces dynamin levels and neuronal cell death – Medical Xpress

By adminAugust 17, 2017Uncategorized

August 16, 2017

A new study has shown that following brain ischemia caused by cerebral blockage in mice both immediate and delayed reduction in body temperature helped limit cell death and levels of a protein called dynamin. These results, which suggest that dynamin may have a role inand be a potential drug target forstroke-related neuronal cell death, are reported in Therapeutic Hypothermia and Temperature Management.

The article entitled "Hypothermia Identifies Dynamin as a Potential Therapeutic Target in Experimental Stroke" is coauthored by Jong Youl Kim, PhD, Nuri Kim, Jong Eun Lee, PhD, and Midori Yenari, MD, University of California, San Francisco and Yonsei University College of Medicine, Seoul, Republic of Korea.

The researchers demonstrated increased expression of dynamin and the cell surface receptor FAS in a mouse model of stroke. They assessed the effects of two cooling approaches on the survival of brain cells: cooling as soon as cerebral blockage occurs (early hypothermia) and cooling that began 1 hour later (delayed hypothermia). The results were compared to those in mice not subjected to hypothermia.

"These exciting results present new injury pathways to target for utilizing therapeutic hypothermia in acute as well as sub-acute time points after stroke," says W. Dalton Dietrich, III, PhD, Editor-in-Chief of Therapeutic Hypothermia and Temperature Management, Scientific Director of The Miami Project to Cure Paralysis, and Kinetic Concepts Distinguished Chair in Neurosurgery, University of Miami Leonard M. Miller School of Medicine.

Explore further: New, faster therapeutic hypothermia techniques

More information: Jong Youl Kim et al, Hypothermia Identifies Dynamin as a Potential Therapeutic Target in Experimental Stroke, Therapeutic Hypothermia and Temperature Management (2017). DOI: 10.1089/ther.2017.0005

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More:
Hypothermia after stroke reduces dynamin levels and neuronal cell death - Medical Xpress

Using barcodes to trace cell development – Medical Xpress

By adminAugust 17, 2017Uncategorized

August 16, 2017 Credit: CC0 Public Domain

How do the multiple different cell types in the blood develop? Scientists have been pursuing this question for a long time. According to the classical model, different developmental lines branch out like in a tree. The tree trunk is composed of stem cells and the branches are made up of various types of progenitor cells that can give rise to a number of distinct cell types. Then it further branches off into the specialized blood cells, i.e., red blood cells, blood platelets and various types of white blood cells that are part of the immune system. In recent years, however, doubts about this model have arisen.

Hans-Reimer Rodewald, a scientist at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg, and his co-workers wanted to capture the dynamic events in blood cell formation instead of merely taking snapshots. In close collaboration with a research team led by systems biologist Thomas Hfer, the scientists have developed a new technology that enables them to precisely follow the developmental tracks of cells. To this end, they label stem cells with a kind of genetic barcode in order to be able to clearly identify their offspring later.

"Genetic barcodes have been developed and applied before, but they were based on methods that can also change cellular properties," Rodewald said. "Our barcodes are different: They can be induced tissue-specifically and directly in the genome of mice - without influencing the animals' physiological development." The basis of the new technology is the so-called Cre/loxP system that is used to rearrange or remove specially labeled DNA segments.

Weike Pei und Thorsten Feyerabend in Rodewald's team bred mice whose genomes exhibit the basic elements of the barcode. At a selected site, where no genes are encoded, it contains nine small DNA fragments from a plant called Arabidopsis thaliana. These elements are flanked by ten genetic cutting sites called IoxP sites. By administering a pharmacological agent, the matching molecular scissors called "Cre" can be activated in the animals' hematopoietic stem cells. Then code elements are randomly rearranged or cut out. "This genetic random DNA barcode generator can generate up to 1.8 million genetic barcodes and we can identify the codes that arise only once in an experiment," Hfer said.

"The mice then do the rest of the work," said Rodewald. When these specially labeled hematopoietic stem cells divide and mature, the barcodes are preserved. In collaboration with the Max Delbrck Center for Molecular Medicine, the researchers have performed comprehensive barcode analyses in order to trace an individual blood cell back to the stem cell from which it originates.

These analyses have revealed that two large developmental branches start out from the hematopoietic stem cells of the mice: In one branch, T cells and B cells of the immune system develop; in the other, red blood cells as well as various other types of white blood cells such as granulocytes and monocytes form. All these cell types can arise from a single stem cell. "Our findings show that the classical model of a hierarchical developmental tree that starts from multipotent stem cells holds true for hematopoiesis," Rodewald emphasized.

The system developed by the Heidelberg researchers can also be used for other purposes besides studying blood cell development. This strategy can basically be applied in any tissue. In the future, it might also be used for experimentally tracing the origin of leukemias and other cancers.

Explore further: Live assessment of blood formation

More information: Weike Pei et al, Polylox barcoding reveals haematopoietic stem cell fates realized in vivo, Nature (2017). DOI: 10.1038/nature23653

Since ancient times, humankind has been aware of how important blood is to life. Naturalists speculated for thousands of years on the source of the body's blood supply. For several centuries, the liver was believed to be ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original post:
Using barcodes to trace cell development - Medical Xpress

Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood … – Markets Insider

By adminAugust 17, 2017Uncategorized

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- Factors driving the growth of this market include the increasing number of genomics research activities for studying diseases; advances in biobanking and the growing trend of conserving cord blood stem cells of newborns; government & private funding to support regenerative medicine research, and the growing need for cost-effective drug discovery and development. On the other hand, the growth of this market is hindered to some extent due to the high cost of automation and issues related to biospecimen sample procurement.

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

"Automated storage is expected to register the highest CAGR during the forecast period" The biobanking market is classified by storage type into manual and automated storage. The automated storage type segment is expected to grow at a higher rate during the forecast period. This is attributed to launch of new and advanced automated storage equipment and increasing demand for the quality storage of samples.

"Regenerative medicine to dominate the market during the forecast period" The biobanking market is segmented based on applications regenerative medicine, life science research, and clinical research. In 2017, the regenerative medicine segment is expected to command the largest share and is also estimated to grow at the fastest rate as compared to other segments. This can be attributed to increasing research activities in the field of regenerative medicine and rising demand for well-annotated and quality biosamples for research.

"Asia-Pacific is estimated to grow at the highest CAGR during the forecast period" Geographically, the biobanking market is dominated by North America, followed by Europe. The Asia-Pacific region is estimated to grow at the fastest rate which can be attributed to the large population in China and India, increasing research in regenerative medicine, and improving life sciences research infrastructure in the region.

The primary interviews conducted for this report can be categorized as follows:

The key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.).

Study Coverage: The report analyses the biobanking market by product and service, sample type, storage type, application and regions. Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market.

Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the type, products, applications, end users, and regions.

Key benefits of buying the Report: This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: rel="nofollow">clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

View original content:http://www.prnewswire.com/news-releases/biobanking-market-by-product-and-serviceequipment-consumables-services-software-sample-type-blood-products-human-tissues-cell-lines-nucleic-acids-application-regenerative-medicine-life-science-clinical-research---g-300505662.html

SOURCE Reportlinker

Read the rest here:
Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood ... - Markets Insider

Blood Test Finds Cancer Before Symptoms Start – NBCNews.com

By adminAugust 17, 2017Uncategorized

Scientists have discovered that dying tumor cells release small pieces of their DNA into the bloodstream. These pieces are called cell-free circulating tumor DNA (ctDNA). National cancer Institute

The test is a long way from being used to screen for cancer, but the study shows a way to get there, the team reported in the journal Science Translational Medicine.

There is a lot of excitement about liquid biopsies, but most of that has been in late-stage cancer or in individuals where you already know what to look for, said Dr. Victor Velculescu, professor of oncology and pathology at the Johns Hopkins University Kimmel Cancer Center.

The surprising result is that we can find a high fraction of early-stage patients having alterations in their blood, said Velculescu, who led the study team.

It was not a slam dunk, but the test found cancer in the blood of more than half the patients who had been diagnosed with stage 1 cancer. It was even more accurate in finding late-stage cancers, but the goal would be to catch cancer in its earliest, easiest-to-treat stage.

There were no false positives in 44 people who did not have cancer, they said.

Several different liquid biopsies are already on the market, used to help track whether cancer treatments are working. But theres nothing yet that can detect cancer in someone who has not yet been diagnosed.

Its easy to find tumor mutations if you know what to look for. The challenge was to develop a blood test that could predict the probable presence of cancer without knowing the genetic mutations present in a persons tumor, Velculescu said.

Velculescus team developed an approach called targeted error correction sequencing (TEC-Seq for short).

We have used this approach to examine 58 cancer-related genes, the team wrote in their report. The method involved deep sequencing sequencing DNA 30,000 times over to look for mutations in DNA from tumor cells that floats in the blood.

Cancer patients had more of this DNA in their blood, the team found.

They identified 62 percent of the patients with stage I cancer four out of eight colon cancer patients, and 90 percent of colon cancer patients with stage II, III or IV disease.

They got a positive in 45 percent of the lung cancer patients with stage I disease, 67 percent of ovarian cancer patients with stage I disease and 67 percent of breast cancer patients with stage I disease.

While that's good, it's not a great result. The test still missed a large percentage of cancers and will need much improvement, Velculescu said.

It will also have to be tried in larger groups of patients, and patients with different cancers. The first goal would be to try it in people at high risk of cancer but no symptoms yet such as smokers, or people with cancer-causing gene mutations like BRCA mutations, Velculescu said.

Catching cancer in its earliest stages could save many lives, he said. Cancer is the No. 2 killer overall in the United States.

The survival difference between late stage and early stage disease in these cancers would account for more than a million lives each year worldwide, Velculescu said.

The genetic sequencing is also expensive right now on the order of several thousand dollars for the 30,000 repeats the team did. But costs are coming down steadily, he said.

Velculescu said Johns Hopkins had patented this test, and Velculescu is himself the founder of a company that does liquid biopsies for advanced cancer patients called Personal Genome Diagnostics.

The U.S. Food and Drug Administration

The agency has chastised a company called

Its also

Currently, colon cancer can be detected very early

Mammograms can detect

See the article here:
Blood Test Finds Cancer Before Symptoms Start - NBCNews.com

Ask the Doctors: Stem cell therapy may help worn-out knees | The … – Bennington Banner (subscription)

By adminAugust 16, 2017Stem Cell Doctors

By Robert Ashley, M.D.

A: "Worn out" is a good way to term what happens to the knee joint with prolonged use. Let's look at how this happens, starting with cartilage.

The lower portion of the knee joint (at the tibia) contains shock absorbers called menisci made of cartilage. You have one on the inner portion and another on the outer portion of each knee. The upper portion of the knee joint (at the femur) is lined with cartilage as well. All of this cartilage helps protect the bones at the joint but it doesn't heal or regenerate well due to limited blood supply. When severe, worn cartilage leads to arthritis of the knee. In knee X-rays of people over the age of 60, 37 percent have shown evidence of arthritis of the knees.

The intriguing thing about stem cells is that they have the ability to become any type of cell that the body needs. The cells used for stem cell injections in the knees are called mesenchymal stem cells, and they can differentiate into bone, fat or cartilage cells. These stem cells can come from the fat cells of your body, from your bone marrow or from the inner lining of your knee joint; they're then replicated in the laboratory and injected into the knee joint.

Here's what the research shows so far ...

In a 2013 study, 32 patients with meniscal tears of the knee were injected with a combination of stem cells, platelet-rich plasma and hyaluronic acid. The study reported improved symptoms and even MRI evidence of meniscal cartilage regeneration.

In a 2014 study, 55 patients who had surgery for meniscal tears of the knees were separated into three groups, with two of the groups receiving stem cell injections. Researchers found that, after six weeks, pain had decreased substantially in the two groups that received stem cell injections and that the decrease was even greater at one and two years after the injection.

In a 2017 study in the British Journal of Sports Medicine, researchers analyzed six studies that used stem cells for osteoarthritis of the knees. In five of the studies, stem cells were given after surgery to the knee; in the other study, stem cells from a donor were administered without surgery. All the studies showed reduced pain and improved knee function. Further, in three of the four trials, MRIs corroborated the cartilage improvements. However, the authors noted, five of the six studies were of such poor methodology that an overall conclusion about the stem cells' effectiveness could not be made.

In all these studies, the most common side effect was knee swelling and stiffness, which improved over time.

There may be benefit to stem cell injections for cartilage loss of the knees, but more data are needed, especially in those who aren't having surgery of the knee. I'd also like to see more data on this type of therapy as a preventive measure for younger patients before their knees are worn out.

Robert Ashley, M.D., is an internist and assistant professor of medicine at the University of California, Los Angeles. Send your questions to askthedoctors@mednet.ucla.edu, or write: Ask the Doctors, c/o Media Relations, UCLA Health, 924 Westwood Blvd., Suite 350, Los Angeles, CA, 90095. Owing to the volume of mail, personal replies cannot be provided.

If you'd like to leave a comment (or a tip or a question) about this story with the editors, please email us. We also welcome letters to the editor for publication; you can do that by filling out our letters form and submitting it to the newsroom.

See original here:
Ask the Doctors: Stem cell therapy may help worn-out knees | The ... - Bennington Banner (subscription)

DHK – Annie McNamara, 27, myelodysplastic syndrome, Boston, with Dr. Robert Soiffer, chief, Hematologic … – WEEI.com

By adminAugust 16, 2017Stem Cell Doctors

Earlier had a guest on that protects it you might just that might we'll just talk music you know but yes I've done and yes. We have another and now I. You felt it just at the time we got her elbow and grad and out whose family owns the Portland sea dogs and I had to admit I'd bounce the first pitch up. Portland seed in their video of this hole and I thought I asked rotate another chance to sit. Her family owns the airport into dogs and there's been. Apparently I Wii I know exactly where to go to the video thank you very much day. Any back to Mary's here and and her doctor doctor Robert Zoellick for. And that any. It's 27 years old hat Milo this plastic syndrome which I have to admit. I've been sixteen of these things but that's a new one on me at I don't think effort that went before what what exactly did in tale. Yes so it's blood disorder again normally found it again. Older folks. So it was sort of rare for at 25. Year old to be diagnosed with that. But certainly shared today is a bone marrow transplant so. I mean was it meant it to Dana Farber once I found out hands. Did three rounds of chemo outpatient acting forever. An and accepting of both Americans and last June. It's as the impatient at the breakdown. That doctor cipher was my transplant doctor and tenth harbor. And doctor Roberts worked for is here and I heard you say yes when she talked about the rarity of the disease how rare is it. How he treated well itself. It's the disease that as Annie said he's much more common old people. People in the 60s80s. Very uncommon. Twenty's. He can be treated with support here medications and little dose chemotherapy when picked Poulter. When patients younger. We generally want to all Americans clause with out of bone marrow transplant mild to split will lead to keep. And it becomes very eager to treat so. Despite the rarity of the disease and he was that. Attracted the entire time she just made it head on. Did it too tough to what I have to do. I'll take the chemotherapy in the transplant her sister was her daughter which is remarkable story also that. She showed remarkable courage through the entire process in and it even knows something was wrong or you feel like how long that laughed. Tired. Too. Much. The bar. Like an appealing their I don't got a good story and that's what you're gonna carry you through the. I cannot relate to that I. But it hadn't had it takes I knew something really often action difficult. Week. So. It's late night after what happened to inch its way. Saturday Javed Ali counted that's very Massachusetts. My word and act out there. That come back. It's. It doctor Lieberman can tear your donor with your sister Molly. I assume that might have been a ten for ten match perhaps. Yes it was an exact match was awesome. Sister is a senior at the academy's actors like frank. Steamers that reflects well. Making sure to keep a schedule worked with the sisters schedule them. In between graduation. Widgets so. I was really fortunate to. Match. A week later after such a perfect. It worked out I was able to hurt at mission. And I. Speaking we transplant a year after the transplant something significant happened in your life tell us what that is and. Yes so I got engaged. Almost. Exactly here after the transplant which was pretty special. Dan my fiance was served with me through the whole ride. So it was awesome very exciting ends. Its focus on planning a wedding now wedges. And that. All of that in the past years. And he was right there was Hewitt said he knows the real deal yeah really just aren't as good as our guys. Yep it's sealed the deal. And had a question for your doctors is finding that match fortunately she had a sister without match there for the bone marrow transplant was once the match but for those who don't have sisters don't have a brother that able to do that how tricky can nappy. Will things really change over the past five to eight years the better. Twenty years ago we would only do bone marrow transplant on a patient who had eight siblings a brother or sister who matched. At about fifteen years ago we started to transplants from unrelated donors volunteers dealers. Who were able to actually provided the source of stem cells and actually good outcomes. More recently we've been able to even use half matches so even a win eight other sister does it. Match fully ten out of ten match dale said a week you actually get by with a five of ten match almost as well as we can't attempt. Our friend Tara who's going to be here tomorrow had her bone marrow transplant in November. And I know she was kind of isolated for about nine months I assume you've had a similar sort of regiment you had to go through. Yes of the first hundred days I was inside you know sort of contact them on in the outside world besides my family. So I was definitely tough and then. I work for an Austin Co. act Clijsters and so I was able to work from home through the spring. And they were awesome. Sort of helping me get through flu season because my immune system. Receivers susceptible to catching something. So yeah I was you know at home until April. Answered just get getting back in readjusted to you. I. It's a real family affair doc watched any buyers Oprah folks beyonc really all came together it. That'll give her support of actually help keep healthy. A community effort. When's the wedding I'd accept. If congratulations a couple of things that couples swapping one you do work out some companies how to increase in credit out of great Fredricka. And secondly in the scouting reports and future sea dogs that we should be looking out or. Bully doesn't devers Africans as loyal you know he's doing pretty well. Commandant and the obviously. I don't have a scouting report right now but I'm sure things. You're in the nickel you need a great little bull market. Yeah it's I'd love going up there and Ankara practice hitting get a chance to. Endeavour's much he was there are very now really kind of scooted through town and yes. Now he's here hitting home runs things like every every game every other game. We took into been intently from you two's yeah. Yeah I'm not a you've got your children to this point yes it's critical to see them say it. Progress. It's to fat cats watch. Well it's great to visit with both of you and MacNamara fallible Malone multi faceted. Can not just in case you didn't hear ripped up. And doctor Robert Lichter thanks you guys that are very much for coming in it's great people that it. Thanks for having classy guys into the past. Thank you thank you and good luck with a wedding thank you and I hear from September whenever that is good luck. Think it's.

Follow this link:
DHK - Annie McNamara, 27, myelodysplastic syndrome, Boston, with Dr. Robert Soiffer, chief, Hematologic ... - WEEI.com

Friends come together for benefit concert for Joni Eickhoff – Grand Island Independent

By adminAugust 16, 2017Stem Cell Clinic

When Dianne Schneider found out her friend and fellow parishioner Joni Eickhoff was trying to raise money to pay for an unconventional medical treatment for her pulmonary cystic fibrosis, she knew what she had to do perform a concert.

Schneider, who is a longtime music minister at St. Marys Cathedral, didnt think she would ever say that. But a few years ago, Eickhoff encouraged Schneider to record a CD of her music with fellow musician Claudette Sekutera. The CD of contemporary Christian music was recorded in 2012 and half of the funds raised by the sale of the CD have gone to benefit St. Marys Cathedral.

She would always come up and say how beautiful the music was and she was the one who always told me I should record a CD, Schneider remembered. She just wanted so much for me to do a concert back then, but I didnt really want to. I dont know if it was that I didnt want to draw the attention to myself or that deep down I didnt think anyone would come.

When Schneider saw the flyer in church asking for donations for Eickhoffs GoFundMe account, she thought differently.

I kept thinking about it and thought that this is the time for a concert because now it has a purpose, she said.

The benefit concert is scheduled for 3 to 4:30 p.m. Sunday at St. Marys Cathedral. Besides Sekutera, Schneider will perform with Amy and Andy Schneider, Jeanne Allen and Sue Stueben. There is no charge to attend, but a freewill offering will be accepted. A group from Woodmens Insurance has offered to match the proceeds. Schneider will also be selling her CD Gratitude for $10, with half of those proceeds going to Eickhoff as well.

Eickhoff was more than just a little surprised by Schneiders offer.

You talk about tears that come down, Eickhoff said. Shes just one of a kind. Shes my guardian angel.

Pulmonary cystic fibrosis is an inherited disease that causes thickened mucus to block airways, making it difficult to breathe.

Diagnosed in 2015, Joni had all but exhausted conventional medical treatments when she and her husband, Ramon, learned about stem cell treatments at a pulmonary clinic in Dallas, Texas.

The cost was prohibitive, though, as the procedure was not covered by Medicare or insurance. The Eickhoff family set up a GoFundMe account to raise $11,000, which included the cost of transportation to and from the clinic. They posted a flyer at St. Marys Cathedral and shortly after that, Eickhoffs husband was approached by another parishioner who offered to cover the entire cost.

The Eickhoffs accepted the offer on the condition that they be able to pay back the gift. The donor agreed and Joni underwent the procedure on April 20 and has been steadily improving. Since the treatment, her husband said, she has gone from being able to take 56 steps without oxygen to 101 steps without oxygen.

Each time we do a walk test without oxygen, her recovery time has gone to five or six minutes, where before it was only a couple of minutes, he said.

It was very successful, Joni said. All I did was sit in a chair.

Eickhoff said drawing the blood at the clinic was a six-hour procedure over the course of two days, three hours each day. When she asked her doctor when she could expect to see results, the doctor told her three to six months.

Im just doing so good, she said, after just a little over three months. Of course, when I talk, it takes a lot of air.

Eickhoff and her husband have been so encouraged by her results, they want to spread the word about stem cell treatments. Ramon said there are five similar clinics in the United States and they advertise an 82 to 83 percent success rate.

If you can do the stem cell treatment, you can be off oxygen, Joni said. There are 150,000 people that are dying that dont have to.

Colleen Gallion is the associate editor of the West Nebraska Register.

Go here to read the rest:
Friends come together for benefit concert for Joni Eickhoff - Grand Island Independent

‘Unexpected fountain of youth’ found in cardiac stem cells, researcher says – FOX31 Denver

By adminAugust 16, 2017Stem Cell Clinic

Cardiac stem cells derived from young hearts helped reverse the signs of aging when directly injected into the old hearts of elderly rats, astudypublished Monday in the European Heart Journal demonstrated.

The old rats appeared newly invigorated after receiving their injections. As hoped, the cardiac stem cells improved heart function yet also provided additional benefits. The rats fur fur, shaved for surgery, grew back more quickly than expected, and their chromosomal telomeres, which commonly shrink with age, lengthened.

The old rats receiving the cardiac stem cells also had increased stamina overall, exercising more than before the infusion.

Its extremely exciting, said Dr. Eduardo Marbn, primary investigator on the research and director of the Cedars-Sinai Heart Institute. Witnessing the systemic rejuvenating effects, he said, its kind of like an unexpected fountain of youth.

Weve been studying new forms of cell therapy for the heart for some 12 years now, Marbn said.

Some of this research has focused on cardiosphere-derived cells.

Theyre progenitor cells from the heart itself, Marbn said. Progenitor cells are generated from stem cells and share some, but not all, of the same properties. For instance, they can differentiate into more than one kind of cell like stem cells, but unlike stem cells, progenitor cells cannot divide and reproduce indefinitely.

From hisown previous research, Marbn discovered that cardiosphere-derived cells promote the healing of the heart after a condition known as heart failure with preserved ejection fraction, which affects more than 50% of all heart failure patients.

Since heart failure with preserved ejection fraction is similar to aging, Marbn decided to experiment on old rats, ones that suffered from a type of heart problem thats very typical of what we find in older human beings: The hearts stiff, and it doesnt relax right, and it causes fluid to back up some, Marbn explained.

He and his team injected cardiosphere-derived cells from newborn rats into the hearts of 22-month-old rats thats elderly for a rat. Similar old rats received a placebo injection of saline solution. Then, Marbn and his team compared both groups to young rats that were 4 months old. After a month, they compared the rats again.

Even though the cells were injected into the heart, their effects were noticeable throughout the body, Marbn said

The animals could exercise further than they could before by about 20%, and one of the most striking things, especially for me (because Im kind of losing my hair) the animals regrew their fur a lot better after theyd gotten cells compared with the placebo rats, Marbn said.

The rats that received cardiosphere-derived cells also experienced improved heart function and showed longer heart cell telomeres.

The working hypothesis is that the cells secrete exosomes, tiny vesicles that contain a lot of nucleic acids, things like RNA, that can change patterns of the way the tissue responds to injury and the way genes are expressed in the tissue, Marbn said.

It is the exosomes that act on the heart and make it better as well as mediating long-distance effects on exercise capacity and hair regrowth, he explained.

Looking to the future, Marbn said hes begun to explore delivering the cardiac stem cells intravenously in a simple infusion instead of injecting them directly into the heart, which would be a complex procedure for a human patient and seeing whether the same beneficial effects occur.

Dr. Gary Gerstenblith, a professor of medicine in the cardiology division of Johns Hopkins Medicine, said the new study is very comprehensive.

Striking benefits are demonstrated not only from a cardiac perspective but across multiple organ systems, said Gerstenblith, who did not contribute to the new research. The results suggest that stem cell therapies should be studied as an additional therapeutic option in the treatment of cardiac and other diseases common in the elderly.

Todd Herron, director of the University of Michigan Frankel Cardiovascular Centers Cardiovascular Regeneration Core Laboratory, said Marbn, with his previous work with cardiac stem cells, has led the field in this area.

The novelty of this bit of work is, they started to look at more precise molecular mechanisms to explain the phenomenon theyve seen in the past, said Herron, who played no role in the new research.

One strength of the approach here is that the researchers have taken cells from the organ that they want to rejuvenate, so that makes it likely that the cells stay there in that tissue, Herron said.

He believes that more extensive study, beginning with larger animals and including long-term followup, is needed before this technique could be used in humans.

We need to make sure theres no harm being done, Herron said, adding that extending the lifetime and improving quality of life amounts to a tradeoff between the potential risk and the potential good that can be done.

Capicor, the company that grows these special cells, is focused solely on therapies for muscular dystrophy and heart failure with ongoing clinical trials involving human patients, Marbn said.

Capicor hasnt announced any plans to do studies in aging, but the possibility exists.

After all, the cells have been proven completely safe in over 100 human patients, so it would be possible to fast-track them into the clinic, Marbn explained: I cant tell you that there are any plans to do that, but it could easily be done from a safety viewpoint.

Excerpt from:
'Unexpected fountain of youth' found in cardiac stem cells, researcher says - FOX31 Denver

Local chiropractor educating patients about stem cell treatments – WZZM

By adminAugust 16, 2017Stem Cell Treatment

Denise Pritchard, WZZM 12:44 PM. EDT August 14, 2017

Woman's Bones

GRAND RAPIDS, MICH. - Stem cell injections are being used to treat all sorts of illness, from joint pain to tissue damage. Dr. Michael Kwast is a chiropractor who's sold on the benefits of stem cell treatments.

He joined The Exchange to explain how they work and describe the results hes seen for patients.

Dr. Kwasts group, Medical Services Providers, is affiliated with the Stem Cell Institute of America.

For more information about stem cell therapy, visit http://www.stemcellgrandrapids.com. Or, you may attend a free seminar on Aug. 21 at 7 p.m. Its at 475 Lake Michigan Dr. NW in Grand Rapids. Register now by calling 616-888-3160.

Make it easy to keep up to date with more stories like this. Download the WZZM 13 app now.

Have a news tip? Email news@wzzm13.com, visit our Facebook page or Twitter.

2017 WZZM-TV

Read more from the original source:
Local chiropractor educating patients about stem cell treatments - WZZM